XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare Biotechnology

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > 1 for 11.74 r/s

<< Previous

Bullboard Posts

Next >>

Comment by SpaceLabson Sep 22, 2021 2:09pm

195 Views

Post# 33899242

RE:RE:1 for 11.74 r/s

Post Bob's pick, why XRX?

We wnt some solid news now from CEO Allen.

Rollback is a No Brainer but Butcher Retail shareholders while big players PLAY you CEO